Survivin expression, apoptosis and proliferation in chronic myelomonocytic leukemia

European Journal of Haematology
Rosangela InvernizziEdoardo Ascari

Abstract

We analyzed the expression of the inhibitor of apoptosis survivin by immunocytochemistry in bone marrow cells from patients with chronic myelomonocytic leukemia (CMML) to evaluate possible abnormalities in comparison with other myelodysplastic (MDS) and myeloproliferative syndromes, and to investigate a possible correlation between survivin expression and altered apoptosis or proliferation, or relevant laboratory and clinical findings. Thirty-four patients with CMML [18 MDS-CMML and 16 myeloproliferative disorder (MPD)-CMML], 90 with MDS, 41 with acute myeloid leukemia (AML), 19 with chronic MPD and 25 control subjects were studied. In normal samples survivin was never detectable. In CMML survivin levels higher than in MDS and AML (P < 0.0001), but similar to those found in MPD were observed. In CMML and MDS apoptosis was significantly higher compared to normal controls and all other subtypes of leukemias (P < 0.0001). Proliferation did not differ significantly in normal controls, MDS and CMML; the lowest levels were observed in AML and MPD (P < 0.0001). In CMML there was no correlation between survivin expression and blast cell percentage, apoptosis or proliferation, FAB or WHO subgroup. Proliferation was higher in MDS-CMML an...Continue Reading

References

Sep 1, 1996·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·A NegoescuE Brambilla
Aug 1, 1997·Nature Medicine·G AmbrosiniD C Altieri
Jun 6, 1998·The Journal of Biological Chemistry·G AmbrosiniD C Altieri
Dec 2, 1999·Nature Genetics·V E VelculescuK W Kinzler
Nov 25, 2000·British Journal of Haematology·C AdidaH Dombret
May 15, 2002·Leukemia Research·Chung Wu LinMaher Albitar
Aug 13, 2002·Nature Medicine·Olivier P Blanc-BrudeDario C Altieri
May 22, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Matthias ZeisAxel Heiser
May 29, 2003·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Hyung Soo HanMidori A Yenari
Jul 30, 2003·Lancet·Paul J KimDario C Altieri
Oct 17, 2003·Hematology/oncology Clinics of North America·John M Bennett
Jan 31, 2004·Annals of the New York Academy of Sciences·Uwe Zangemeister-Wittke
Jun 24, 2004·Journal of Cellular Biochemistry·Dario C Altieri
Sep 14, 2004·Leukemia & Lymphoma·U GermingN Gattermann
Sep 17, 2004·Biochemical and Biophysical Research Communications·Seiji Fukuda, Louis M Pelus
Sep 24, 2004·Leukemia Research·Kouhei YamamotoMasanobu Kitagawa
Oct 27, 2004·Apoptosis : an International Journal on Programmed Cell Death·A Wrzesień-KuśT Robak
Oct 30, 2004·Leukemia & Lymphoma·Rosangela InvernizziEdoardo Ascari
Dec 1, 2004·The Hematology Journal : the Official Journal of the European Haematology Association·Ingo TammChristian Wuchter
Mar 31, 2005·Blood·John C Reed, Maurizio Pellecchia
Jun 1, 2005·Cancer Letters·Enrico ConteAngelo Messina
Jul 16, 2005·Leukemia & Lymphoma·Juan-Carlos Hernández-BoludaFrancisco Cervantes

❮ Previous
Next ❯

Citations

Feb 17, 2009·World Journal of Urology·Giueng-Chueng WangJong-Shiaw Jin
Dec 16, 2011·Current Hematologic Malignancy Reports·Madappa N KundrandaRuben A Mesa
Apr 24, 2008·Human Molecular Genetics·Bozena NovotnaYana Bagryantseva
Aug 21, 2007·Leukemia Research·Semra PaydasUmut Disel
Jul 16, 2008·Expert Opinion on Therapeutic Targets·S M C LangemeijerJ H Jansen

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Adult Stem Cells

Adult stem cells reside in unique niches that provide vital cues for their survival, self-renewal, and differentiation. They hold great promise for use in tissue repair and regeneration as a novel therapeutic strategies. Here is the latest research.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis